{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T23:04:54Z","timestamp":1648854294788},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":2974,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1093\/annonc\/mdr410","type":"journal-article","created":{"date-parts":[[2011,8,31]],"date-time":"2011-08-31T00:14:07Z","timestamp":1314749647000},"page":"2157-2159","source":"Crossref","is-referenced-by-count":6,"title":["Grading system and management guidelines for dermatitis induced by head and neck radiotherapy plus cetuximab: clinical validation required"],"prefix":"10.1016","volume":"22","author":[{"given":"J.A.","family":"Langendijk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.F.","family":"Oosting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1093\/annonc\/mdr410_bb0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"issue":"9538","key":"10.1093\/annonc\/mdr410_bb0015","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(06)69121-6","article-title":"Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis","volume":"368","author":"Bourhis","year":"2006","journal-title":"Lancet"},{"issue":"17","key":"10.1093\/annonc\/mdr410_bb0020","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1093\/annonc\/mdr410_bb0025","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1093\/annonc\/mdr410_bb0030","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1093\/annonc\/mdr410_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdr410_bb0040","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2008.09.007","article-title":"High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes","volume":"90","author":"Giro","year":"2009","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdr410_bb0045","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.radonc.2008.09.018","article-title":"Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer","volume":"90","author":"Pryor","year":"2009","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdr410_bb0050","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.radonc.2009.05.005","article-title":"Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer","volume":"93","author":"Chan","year":"2009","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdr410_bb0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijrobp.2010.05.018","article-title":"Grade 3\/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT","volume":"81","author":"Studer","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdr410_bb0060","article-title":"Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck","author":"Suntharalingam","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1093\/annonc\/mdr410_bb0065","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1118\/1.3553406","article-title":"Dosimetric verification of surface and superficial doses for head and neck IMRT with different PTV shrinkage margins","volume":"38","author":"Shiau","year":"2011","journal-title":"Med Phys"},{"key":"10.1093\/annonc\/mdr410_bb0070","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/annonc\/mdr139","article-title":"Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines","volume":"22","author":"Bernier","year":"2011","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdr410_bb0075","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.ijrobp.2007.04.054","article-title":"Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency","volume":"69","author":"Davidson","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1093\/annonc\/mdr410_bb0080","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/01.coc.0000138965.97476.0f","article-title":"Preliminary reliability and validity testing of a new Skin Toxicity Assessment Tool (STAT) in breast cancer patients undergoing radiotherapy","volume":"27","author":"Berthelet","year":"2004","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdr410_bb0085","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/annonc\/mdm400","article-title":"Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck","volume":"19","author":"Bernier","year":"2008","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdr410_bb0090","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00066-011-2217-7","article-title":"Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab","volume":"187","author":"Selzer","year":"2011","journal-title":"Strahlenther Onkol"},{"issue":"34","key":"10.1093\/annonc\/mdr410_bb0095","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419377609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419377609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/10\/2157\/652631\/mdr410.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:47:36Z","timestamp":1624438056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419377609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0923753419377609"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr410","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}